1246765-27-4

Usage

Uses

Used in Organic Synthesis:
Methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its boronate ester functional group facilitates cross-coupling reactions, enabling the formation of carbon-carbon bonds that are crucial for the synthesis of target compounds.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate is used as a building block for the development of new drugs. Its unique structure and reactivity allow for the synthesis of bioactive molecules with potential therapeutic applications.
Used in Agrochemical Synthesis:
Methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate is also utilized in the synthesis of agrochemicals, such as pesticides and herbicides. Its ability to form carbon-carbon bonds through cross-coupling reactions contributes to the development of novel and effective agrochemicals for agricultural applications.
Used in Material Science:
In the field of material science, methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate is employed in the synthesis of advanced materials with specific properties. Its versatility in forming carbon-carbon bonds allows for the creation of materials with tailored characteristics for various applications, such as electronics, energy storage, and polymers.

Upstream product

• 65515-32-4 methyl 6-chloro-2-methoxypyridine-3-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 67367-26-4 2-methoxynicotinic acid methyl ester 
• 65515-28-8 methyl 2,6-dichloronicotinate 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 

Downstream Products

• 1246765-51-4 methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate 
• 1246765-52-5 (R)-methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate 
• 1246765-54-7 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid 
• 1350884-15-9 C₁₆H₁₆N₂O₆ 
• 1246766-12-0 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N-methylnicotinamide 
• 1246766-15-3 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N,N-dimethylnicotinamide 
• 1246766-25-5 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N-(methylsulfonyl)nicotinamide 
• 1246766-21-1 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxy-N-(1H-tetrazol-5-yl)nicotinamide 

Relevant academic research and scientific papers

Iridium-catalyzed C-H borylation of pyridines

The iridium-catalysed C-H borylation is a valuable and attractive method for the preparation of aryl and heteroaryl boronates. However, application of this methodology for the preparation of pyridyl and related azinyl boronates can be challenged by low reactivity and propensity for rapid protodeborylation, particularly for a boronate ester ortho to the azinyl nitrogen. Competition experiments have revealed that the low reactivity is due to inhibition of the active catalyst through coordination of the azinyl nitrogen lone pair at the vacant site on the iridium. This effect can be overcome through the incorporation of a substituent at C-2. Moreover, when this is sufficiently electron-withdrawing protodeborylation is sufficiently slowed to permit isolation and purification of the C-6 boronate ester. Following functionalization, reduction of the directing C-2 substituent provides the product arising from formal ortho borylation of an unhindered pyridine ring. This journal is the Partner Organisations 2014.

Synthesis and cross coupling of a highly substituted 2-pyridylboronate: Application to the large scale synthesis of a mineralocorticoid antagonist

The large scale synthesis of functionalized 2-pyridylboronate 8 and optimization of its Suzuki-Miyaura coupling to chloropyrazoline (R)-7 to provide a scalable synthesis of mineralocorticoid antagonist (R)-1 is described.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.